Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor presented as a sterile solution for intravenous infusion. It replaces deficient factor VIII in patients with hemophilia A and related bleeding disorders. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Octanate is used to manage bleeding disorders that involve factor VIII deficiency. - Hemophilia A (congenital): provides factor VIII replacement to prevent or control bleeding episodes. - Acquired hemophilia A: supplies exogenous factor VIII to restore clotting function. - Peri‑operative management: ensures adequate haemostasis during surgery or invasive procedures. - Prophylaxis in severe hemophilia A: maintains trough factor levels to reduce spontaneous bleeds.

Octanate may be associated with adverse reactions following administration.

Common Side Effects: - Headache: mild to moderate intensity. - Fever: transient elevation of body temperature. - Infusion site reactions: redness, swelling, or pain. - Nausea: occasional gastrointestinal discomfort. - Mild rash: localized skin irritation.

Serious or Rare Side Effects: - Development of inhibitors: neutralising antibodies against factor VIII. - Anaphylactic reaction: severe allergic response requiring emergency care. - Thromboembolic events: clot formation in veins or arteries. - Viral transmission: risk of blood‑borne pathogen transmission despite viral inactivation.

Octanate should be used with careful clinical monitoring. - Allergy assessment: evaluate for known hypersensitivity to plasma‑derived products. - Inhibitor testing: regularly assess for anti‑factor VIII antibodies. - Surgical planning: coordinate dosing with surgical teams to ensure haemostasis. - Concomitant anticoagulants: adjust therapy to avoid excessive bleeding. - Pediatric use: dose and monitoring must be individualized for children. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanate may interact with other agents affecting coagulation.

Major Interactions (Avoid): - Bypassing agents (e.g., activated prothrombin complex concentrates): may increase thrombotic risk. - High‑dose vitamin K antagonists: can exacerbate bleeding if not managed.

Moderate Interactions (Monitor Closely): - Antifibrinolytics (e.g., tranexamic acid): may enhance clot stability, monitor for thrombosis. - Immunosuppressants: could affect inhibitor development. - Other plasma‑derived products: assess cumulative factor load.